High Point, North Carolina-based vTv Therapeutics announced positive results from a mechanistic study of TTP399 in type 1 diabetes patients. 

In October 2020, the government recommended against kids going trick-or-treating for Halloween out of fear of Covid-19 spread. For Halloween 2021, kids have been given the green light to knock on doors.

A safety concern forced Takeda Pharmaceutical to suspend the dosing of patients in two Phase II studies of an experimental treatment for narcolepsy. The clinical trial halt came one day after the company forged a gene therapy agreement with Selecta Biosciences valued at $1.1 billion.

Johnson & Johnson submitted data to the U.S. Food and Drug Administration for emergency use authorization of a booster shot of the company’s Covid-19 vaccine in people aged 18 and older.

AstraZeneca

AstraZeneca requested emergency use authorization from U.S. regulators for the company’s new treatment to prevent Covid-19 for people who respond poorly to vaccines because of a weakened immune system.

The effectiveness of the Pfizer Inc./BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47 percent from 88 percent six months after the second dose, according to data published on Oct. 4 that U.S. health agencies considered when deciding on the need for booster shots.

Janssen Pharmaceutical’s experimental vaccine for a respiratory syncytial virus (RSV) demonstrated an 80 percent efficacy level in adults over the age of 65 years.

Amgen sign Thousand Oaks California

Four months after forging a collaboration to develop an experimental atopic dermatitis treatment, Amgen and Japan’s Kyowa Kirin are beginning to see the fruits of that deal with positive Phase II data for AMG 451/KHK4083, a potential first-in-class anti-OX40 monoclonal antibody.

Biogen

Sage Therapeutics and Biogen announced positive and consistent results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder (MDD) and postpartum depression (PPD).

Germany’s Merck KGaA and Britain’s GlaxoSmithKline on Thursday ended their collaboration on the cancer treatment bintrafusp alfa, once seen as one of Merck’s most promising experimental drugs.